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Patients with previously untreated extensive-disease small-cell lung cancer were treated with irinotecan 60mgm
 2 on days 1 and 8
and cisplatin 60mgm
 2 on day 1 with (n¼55) or without (n¼54) etoposide 50mgm
 2 on days 1–3 with granulocyte colony-
stimulating factor support repeated every 3 weeks for four cycles. The triplet regimen was too toxic to be considered for further
studies.
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Small-cell lung cancer (SCLC), which accounts for approximately
14% of all malignant pulmonary tumours, is an aggressive
malignancy with a propensity for rapid growth and early
widespread metastases (Jackman and Johnson, 2005). A combina-
tion of cisplatin and etoposide (PE) has been the standard
treatment, with response rates ranging from 60 to 90% and median
survival times (MSTs) from 8 to 11 months in patients with
extensive disease (ED)-SCLC (Fukuoka et al, 1991; Roth et al,
1992). A combination of irinotecan and cisplatin (IP) showed a
significant survival benefit over the PE regimen (MST: 12.8 vs 9.4
months, P¼0.002) in a Japanese phase III trial for ED-SCLC (Noda
et al, 2002), although another phase III trial comparing these
regimens failed to show such a benefit (Hanna et al, 2006). Thus,
irinotecan, cisplatin and etoposide are the current key agents in
the treatment of SCLC. A phase II trial of the three agents, IPE
combination, in patients with ED-SCLC showed a promising
antitumour activity with a response rate of 77%, complete
response (CR) rate of 17% and MST of 12.9 months (Sekine
et al, 2003).
We have developed these IP and IPE regimens in a 4-week
schedule where irinotecan was given on days 1, 8 and 15. The dose
of irinotecan on day 15, however, was frequently omitted because
of toxicity in both regimens (Noda et al, 2002; Sekine et al, 2003).
The objectives of this study were to evaluate the toxicities and
antitumour effects of IP and IPE regimens in the 3-week schedule
in patients with ED-SCLC and to select the right arm for
subsequent phase III trials.
PATIENTS AND METHODS
Patient selection
Patients were enrolled in this study if they met the following
criteria: (1) a histological or cytological diagnosis of SCLC; (2) no
prior treatment; (3) measurable disease; (4) ED, defined as having
distant metastasis or contralateral hilar lymph node metastasis; (5)
performance status of 0–2 on the Eastern Cooperative Oncology
Group (ECOG) scale; (6) predicted life expectancy of 3 months or
longer; (7) age between 20 and 70 years; (8) adequate organ
function as documented by a white blood cell (WBC) count
X4.0 10
3ml
 1, neutrophil count X2.0 10
3ml
 1, haemoglobin
X9.5gdl
 1, platelet count X100 10
3ml
 1, total serum
bilirubinp1.5mgdl
 1, hepatic transaminasesp100IUl
 1, serum
creatinine p1.2mgdl
 1, creatinine clearance X60mlmin
 1, and
PaO2 X60torr; and (9) providing written informed consent.
Patients were not eligible for the study if they had any of the
following: (1) uncontrollable pleural, pericardial effusion or
ascites; (2) symptomatic brain metastasis; (3) active infection;
(4) contraindications for the use of irinotecan, including
diarrhoea, ileus, interstitial pneumonitis and lung fibrosis; (5)
synchronous active malignancies; (6) serious concomitant medical
Received 15 October 2007; revised 2 January 2008; accepted 9 January
2008; published online 5 February 2008
*Correspondence: Dr I Sekine, Division of Internal Medicine and
Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1,
Chuo-ku, Tokyo 104-0045, Japan; E-mail: isekine@ncc.go.jp
British Journal of Cancer (2008) 98, 693–696
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sillness, including severe heart disease, uncontrollable diabetes
mellitus or hypertension; or (7) pregnancy or breast feeding.
Treatment schedule
In the IP arm, cisplatin, 60mgm
 2, was administered intra-
venously over 60min on day 1 and irinotecan, 60mgm
 2, was
administered intravenously over 90min on days 1 and 8.
Prophylactic granulocyte colony-stimulating factor (G-CSF) was
not administered in this arm. In the IPE arm, cisplatin and
irinotecan were administered at the same dose and schedule as
the IP arm. In addition, etoposide, 50mgm
 2, was administered
intravenously over 60min on days 1–3. Filgrastim 50mgm
 2 or
lenograstim 2mgkg
 1 was subcutaneously injected prophylacti-
cally from day 5 to the day when the WBC count exceeded
10.0 10
3ml
 1. Hydration (2500ml) and a 5HT3 antagonist were
given on day 1, followed by an additional infusion if indicated in
both arms. These treatments were repeated every 3 weeks for a
total of four cycles.
Toxicity assessment, treatment modification and response
evaluation
Toxicity was graded according to the NCI Common Toxicity
Criteria version 2.0.
Doses of anticancer agents in the following cycles were modified
according to toxicity in the same manner in both arms. Objective
tumour response was evaluated according to the Response
Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al,
2000).
Study design, data management and statistical
considerations
This study was designed as a multi-institutional, prospective
randomised phase II trial. This study was registered on 6
September 2005 in the University hospital Medical Information
Network (UMIN) Clinical Trials Registry in Japan (http://
www.umin.ac.jp/ctr/index.htm), which is acceptable to the Inter-
national Committee of Medical Journal Editors (ICMJE) (http://
www.icmje.org/faq.pdf). The protocol and consent form were
approved by the Institutional Review Board of each institution.
Patient registration and randomisation were conducted at the
Registration Center. No stratification for randomisation was
performed in this study. The sample size was calculated according
to the selection design for pilot studies based on survival (Liu et al,
1993). Assuming that (1) the survival curve was exponential for
survivals; (2) the MST of the worse arm was 12 months and that of
the better arm was 12 months 1.4; (3) the correct selection
probability was 90%; and (4) additional follow-up in years after the
end of accrual was 1 year, the estimated required number of
patients was 51 for each arm. Accordingly, 55 patients for each arm
and their accrual period of 24 months were planned for this study.
The dose intensity of each drug was calculated for each patient
using the following formula as previously described:
The dose intensityðmgm 2 week
 1Þ
¼
Totalmilligramsof adruginallcyclesperbodysurfacearea
Totaldaysof therapy=7
where total days of therapy is the number of days from day 1 of
cycle 1 to day 1 of the last cycle plus 21 days for both arms
(Hryniuk and Goodyear, 1990).
Differences in the reason for termination of the treatment and
the frequencies of grade 3–4 toxicities were assessed by w tests.
Survival was measured as the date of randomisation to the date of
death from any cause or the date of the most recent follow-up for
overall survival and to the date of disease progression or the date
of death for progression-free survival (PFS). The survival of the
arms was estimated by the Kaplan–Meier method and compared
in an exploratory manner with log-rank tests (Armitage et al,
2002).
RESULTS
Patient characteristics
From March 2003 to May 2005, 55 patients were randomised to IP
and 55 patients to IPE. One patient in the IP arm was excluded
because the patient was ineligible and did not receive the study
treatment. The remaining 109 patients were included in the
analyses of toxicity, tumour response and patient survival. There
were no differences between the two arms in any demographic
characteristics listed (Table 1).
Treatment delivery
Treatment was well tolerated with respect to the number of cycles
delivered in both arms (Table 2). Among reasons for termination
of the treatment, disease progression was noted in nine (17%)
Table 1 Patient characteristics
IP (n¼54) IPE (n¼55)
Sex
Female 11 8
Male 43 47
Age (years)
Median (range) 63 (42–70) 62 (48–70)
PS
01 1 1 2
14 2 4 1
21 2
Weight loss
0–4% 38 43
5–9% 10 10
X10% 6 2
Table 2 Treatment delivery
IP (n¼54) IPE (n¼55)
No. (%) No. (%)
Number of cycles delivered
6
a — 1 (2)
4 41 (76) 36 (65)
3 6 (11) 6 (11)
2 3 (6) 6 (11)
1 4 (7) 6 (11)
Reasons for termination of the treatment
w
Completion 40 (74) 35 (64)
Disease progression 9 (17) 2 (4)
Toxicity 3 (6) 13 (24)
Patient refusal 2 (4) 4 (7)
Others 0 (0) 1 (2)
Total number of cycles delivered 192 (100) 186 (100)
Total number of omission on day 8 35 (18) 37 (17)
Total number of cycles with dose reduction 28 (15) 31 (17)
wP¼0.013 by w
2 test.
aProtocol violation.
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spatients in the IP arm and in two (4%) patients in the IPE arm,
whereas toxicity was noted in three (6%) patients in the IP arm and
13 (24%) patients in the IPE arm (P¼0.013) (Table 2). The dose of
irinotecan on day 8 was omitted in 35 (18%) cycles in the IP arm
and 37 (17%) cycles in the IPE arm (Table 2). The total dose and
dose intensity of cisplatin and etoposide were similar between the
IP and IPE arms in the present study (Table 3).
Toxicity
The myelotoxicity was more severe in the IPE arm (Table 4). Grade
3 febrile neutropaenia was noted in 5 (9%) patients in the IP arm
and 17 (31%) patients in the IPE arm (P¼0.005). Packed red blood
cells were transfused in 4 (7%) patients in the IP regimen and 14
(26%) patients in the IPE regimen (P¼0.011). Platelet concen-
trates were needed in none in the IP regimen and 2 (4%) patients
in the IPE regimen (P¼0.16). Grade 3–4 diarrhoea was observed
in 8 (15%) patients in the IP arm and 13 (24%) patients in the IPE
arm (P¼0.262). Grade 3–4 fatigue was more common in the IPE
arm with marginal significance (2 vs 11%, P¼0.054). The severity
of other non-haematological toxicities did not differ significantly
between the arms. No treatment-related death was observed in this
study.
Response, treatment after recurrence and survival
Four CRs and 37 partial responses (PRs) were obtained in the IP
arm, resulting in the overall response rate of 76 with 95%
confidence interval (CI) of 65–87%, whereas six CRs and 42 PRs
were obtained in the IPE arm, and the overall response rate was
87% with a 95% CI of 79–96% (P¼0.126). Median PFS was 4.8
months (95% CI, 4.0–5.6) in the IP and 5.4 months (95% CI, 4.8–
6.0) in the IPE arm (P¼0.049) (Figure 1A). After recurrence, 22
(44%) patients in the IP arm and 8 (16%) patients in the IPE arm
received etoposide-containing chemotherapy. The MST and 1-year
survival rate were 12.4 months (95% CI, 9.7–15.1) and 54.8% (95%
CI, 41.4–68.2%) in the IP and 13.7 months (95% CI, 11.9–15.5)
and 61.5% (95% CI, 48.6–74.4%) in the IPE arm (P¼0.52),
respectively (Figure 1B).
DISCUSSION
This study showed that the IPE regimen in a 3-week schedule with
CSF support produced a promising response rate, PFS and overall
survival. Haematological toxicity in the IPE arm, however, was
very severe in spite of the G-CSF support with the grade 3 febrile
neutropaenia noted in 31% of patients.
In comparison between the 3-week IPE regimen in this study
and the 4-week IPE regimen in the previous study, the delivery of
cisplatin and etoposide was improved in the 3-week IPE regimen
when compared with the 4-week IPE regimen at the cost of the
irinotecan total dose. The response rate and MST were 87% and
13.7 months, respectively, in the 3-week IPE regimen and 77% and
12.9 months in the previous 4-week schedule, and toxicity profiles
were comparable to each other (Sekine et al, 2003).
The MST of 12.4 months in the IP arm in this study was
comparable to that of the previous phase III study, with an MST of
12.8 months (Noda et al, 2002). Thus, this study showed the
reproducible excellent survival outcome of patients with ED-SCLC
who were treated with the IP combination. In contrast, a recent
American phase III study of the PE regimen vs IP regimen failed to
show the superiority of the IP regimen to the PE regimen; the MST
Table 3 Total dose and dose intensity
3-week regimens in this study 4-week regimen
a
IP (n¼54) IPE (n¼55) IPE (n¼30)
Median (range) Median (range) Median (range)
Total dose (mgm
 2)
Cisplatin 240 (60–240) 240 (60–360) 240 (60–240)
Irinotecan 420 (60–480) 390 (60–720) 563 (60–720)
Etoposide 0 600 (150–900) 600 (150–600)
Dose intensity (mgm
 2week
 1)
Cisplatin 19 (14–25) 20 (16–34) 15 (12–15)
Irinotecan 33 (14–40) 35 (15–55) 35 (19–45)
Etoposide 0 48 (34–68) 37 (28–38)
aFrom our previous study (Sekine et al, 2003).
Table 4 Grade 3–4 toxicities
IP (n¼54) IPE (n¼55)
Grade 3 4 3+4 (%) Grade 3 4 3+4 (%)
Leukocytopaenia 9 1 10 (19) 18 11 29 (53)*
Neutropaenia 17 11 28 (52) 24 28 52 (95)*
Anaemia 18 0 18 (25) 16 9 25 (45)
Thrombocytopaenia 2 0 2 (4) 13 0 13 (13)
w
Febrile neutropaenia 5 0 5 (9) 17 0 7 (13)
Diarrhoea 8 0 8 (15) 11 2 13 (24)
Vomiting 4 0 4 (7) 3 0 3 (5)
Fatigue 1 0 1 (2) 5 1 6 (11)
z
Hyponatraemia 9 3 12 (22) 11 2 13 (24)
AST elevation 0 0 0 (0) 3 0 3 (5)
CRN elevation 1 0 1 (2) 0 0 0 (0)
*Po0.001;
wPo0.01; and
zP¼0.054 by w
2 test.
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Figure 1 Progression-free survival (A) and overall survival (B). Thick line indicates the IPE regimen and thin line indicates the IP regimen.
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sfor the PE regimen was 10.2 months and that for the IP regimen
was 9.3 months (Hanna et al, 2006). The discrepancy between the
Japanese and American trials may be explained by the different
cisplatin dose schedules; cisplatin was delivered at a dose of
60mgm
 2 on day 1 every 3 or 4 weeks in the Japanese trials,
whereas cisplatin was delivered at a dose of 30mgm
 2 on days 1
and 8 every 3 weeks in the American one. A platinum agent
administered at divided doses was associated with poor survival in
patients with ED-SCLC in our previous randomised phase II study
(Sekine et al, 2003).
The issue of adding further agents to the standard doublet
regimen has been investigated in patients with ED-SCLC. The
addition of ifosfamide or cyclophosphamide and epirubicin to the
cisplatin and etoposide combination produced a slight survival
benefit, but at the expense of greater toxicity (Loehrer et al, 1995;
Pujol et al, 2001). Phase III trials of cisplatin and etoposide with or
without paclitaxel showed unacceptable toxicity with 6–13% toxic
deaths in the paclitaxel-containing arm (Mavroudis et al, 2001;
Niell et al, 2005). The results in these studies and the current study
are consistent in the increased toxicity despite the G-CSF support
and no definite survival benefit in the three or four drug
combinations over the standard doublet in patients with ED-SCLC.
In conclusion, the IPE regimen was marginally more effective
than the IP regimen, but was too toxic despite the administration
of prophylactic G-CSF.
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